Tumor News and Research

RSS

Non-coding RNA MALAT1 influences lung cancer metastasis

The vast majority - approximately 80 percent - of our DNA does not code for proteins, yet it gets transcribed into RNA. These RNA molecules are called non-coding and fulfill multiple tasks in the cell. Alongside a well-studied group of small RNAs, there is also a class of so-called long non-coding RNAs consisting of more than 200 nucleotides.

6 Feb 2013

Verastem commences VS-6063 plus paclitaxel Phase 1/1b trial in advanced ovarian cancer

Verastem, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced the initiation of a Phase 1/1b trial of VS-6063 in combination with paclitaxel for the treatment of advanced ovarian cancer.

5 Feb 2013

Acceleron Pharma initiates dalantercept phase 2 study in advanced ovarian cancer

Acceleron Pharma, a biopharmaceutical company developing protein therapeutics for cancer and orphan disease, today announced that the Gynecologic Oncology Group (GOG) initiated a phase 2 study of dalantercept in patients with persistent or recurrent ovarian, fallopian tube, or primary peritoneal cancer.

5 Feb 2013

Subclinical hypothyroidism not prognostic in thyroid carcinoma

Subclinical hypothyroidism is not an independent predictor for clinical outcomes in patients with papillary thyroid carcinoma, research shows.

5 Feb 2013

Regular exercise reduces development of painful diabetic neuropathy in animals

Regular exercise reduces the development of painful diabetic neuropathy in animals—apparently related to increased expression of a protective substance called "heat shock protein" 72 (Hsp72), reports an experimental study in the February issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).

5 Feb 2013

MammaPrint breast cancer test can help women avoid chemotherapy

The MammaPrint breast cancer test can dramatically reduce the number of women who need to undergo chemotherapy to treat the disease, according to a newly published study.

5 Feb 2013

Results from Merck’s Vorinostat phase 1 trial on lymphoma

Patients whose aggressive lymphomas have relapsed or failed to respond to the current front-line chemotherapy regimen now have an effective second line of attack against their disease.

5 Feb 2013

An Introduction to the LV200 Bioluminescence Microscope

News-Medical speaks to Robert Schmalzigaug to explore the field of bioluminescence imaging and the applications of the LV200 microscope.

From Evident Corporation - Life Sciences 5 Feb 2013

Novian Health completes $11M funding round

Novian Health, developer of Novilase Breast Therapy, announced today that it has successfully completed a funding round totaling $11 million.

5 Feb 2013

New gold nanoparticle can transport powerful radioactive particles directly to tumors

We've all heard that "it's not wise to use a cannon to kill a mosquito." But what if you could focus the cannon's power to concentrate power into a tiny space? In a new study, University of Missouri researchers have demonstrated the ability to harness powerful radioactive particles and direct them toward small cancer tumors while doing negligible damage to healthy organs and tissues.

5 Feb 2013

Accumulation of passenger mutations can slow or even halt tumor growth

A typical cancer cell has thousands of mutations scattered throughout its genome and hundreds of mutated genes. However, only a handful of those genes, known as drivers, are responsible for cancerous traits such as uncontrolled growth. Cancer biologists have largely ignored the other mutations, believing they had little or no impact on cancer progression.

5 Feb 2013

Immune system can use melanoma's own proteins to kill off cancer cells

Though a small group of proteins, the family called Ras controls a large number of cellular functions, including cell growth, differentiation, and survival. And because the protein has a hand in cellular division, mutated Ras, which can be detected in one-third of all tumors, contributes to many human cancers by allowing for the rapid growth of diseased cells.

5 Feb 2013

Cause of esodeviation differs in children, adults

Children who present with acute-onset esodeviation should be investigated for underlying central nervous system disorders, study findings indicate.

4 Feb 2013

Cloaked nanoparticles escape immune system surveillance to reach desired target

By cloaking nanoparticles in the membranes of white blood cells, scientists at The Methodist Hospital Research Institute may have found a way to prevent the body from recognizing and destroying them before they deliver their drug payloads. The group describes its "LeukoLike Vectors", or LLVs, in the January issue of Nature Nanotechnology.

4 Feb 2013

PKCζ protein plays a critical role in regulating tumor metabolism

Cancer cells need food to survive and grow. They're very good at getting it, too, even when nutrients are scarce. Many scientists have tried killing cancer cells by taking away their favorite food, a sugar called glucose. Unfortunately, this treatment approach not only fails to work, it backfires-glucose-starved tumors actually get more aggressive.

2 Feb 2013

Quantum dots can rapidly deliver calcitriol to targeted tumor sites for treatment of IBC

The shortened daylight of a Maine winter may make for long, dark nights - but it has shone a light on a novel experimental approach to fighting inflammatory breast cancer (IBC), an especially deadly form of breast cancer.

2 Feb 2013

Researchers determine differences in stiffness between healthy and cancerous tissue

The texture of breast cancer tissue differs from that of healthy tissue. Using a cutting-edge tissue diagnostic device, a group of researchers in Basel, Switzerland, has determined one key difference: cancerous tissue is a mix of stiff and soft zones, whereas healthy tissue has uniform stiffness.

2 Feb 2013

University of Kentucky professor to continue research into ruthenium-based cancer drugs

University of Kentucky assistant professor of chemistry Edith "Phoebe" Glazer has received an American Cancer Society Research Scholar Grant for $715,000 over four years to continue her research into ruthenium-based cancer drugs. These compounds are less toxic to healthy cells than a similar and widely used inorganic drug.

1 Feb 2013

Two-step personalized immunotherapy safe for patients with ovarian cancer

Most ovarian cancer patients are diagnosed with late stage disease that is unresponsive to existing therapies. In a new study, researchers from the Perelman School of Medicine at the University of Pennsylvania School of Medicine show that a two-step personalized immunotherapy treatment - a dendritic cell vaccine using patients' own tumor followed by adoptive T cell therapy - triggers anti-tumor immune responses in these type of patients.

1 Feb 2013

Scientists identify specific p53 pocket that can be targeted by cancer-fighting drugs

UC Irvine biologists, chemists and computer scientists have identified an elusive pocket on the surface of the p53 protein that can be targeted by cancer-fighting drugs. The finding heralds a new treatment approach, as mutant forms of this protein are implicated in nearly 40 percent of diagnosed cases of cancer, which kills more than half a million Americans each year.

1 Feb 2013